Alpha Cognition (NASDAQ:ACOG) Shares Break Above 50-Day Moving Average - Should You Sell?

Alpha Cognition logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Alpha Cognition shares rose 2.9% and traded at $8.85, moving above their 50-day moving average of $8.66.
  • Analyst views are mixed: Wall Street Zen downgraded the stock to “sell,” while five analysts rate it “buy.” The consensus price target is $18.20.
  • The company reported quarterly revenue of $7.78 million, above estimates of $7.04 million, but its loss per share of $0.35 slightly missed expectations.
  • Five stocks to consider instead of Alpha Cognition.

Alpha Cognition Inc. (NASDAQ:ACOG - Get Free Report)'s share price passed above its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $8.66 and traded as high as $8.90. Alpha Cognition shares last traded at $8.85, with a volume of 108,104 shares changing hands.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Wall Street Zen lowered shares of Alpha Cognition from a "hold" rating to a "sell" rating in a research note on Saturday, November 14th. Raymond James Financial set a $21.00 target price on shares of Alpha Cognition and gave the company an "outperform" rating in a research note on Thursday, November 12th. B. Riley Financial began coverage on Alpha Cognition in a report on Thursday, August 20th. They issued a "buy" rating and a $21.00 price target for the company. Craig Hallum reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Alpha Cognition in a research report on Friday, August 14th. Finally, HC Wainwright lifted their price target on Alpha Cognition from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Monday, August 17th. Five research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $18.20.

Read Our Latest Report on ACOG

Alpha Cognition Stock Up 2.9%

The firm has a market capitalization of $195.05 million, a PE ratio of -6.46 and a beta of 2.32. The stock has a 50-day moving average price of $8.66 and a 200 day moving average price of $7.35.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) last posted its quarterly earnings data on Wednesday, November 11th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). Alpha Cognition had a negative return on equity of 52.80% and a negative net margin of 147.26%. The company had revenue of $7.78 million for the quarter, compared to analyst estimates of $7.04 million. As a group, equities analysts predict that Alpha Cognition Inc. will post -1.27 earnings per share for the current fiscal year.

Institutional Trading of Alpha Cognition

Hedge funds have recently bought and sold shares of the business. Opaleye Management Inc. lifted its position in Alpha Cognition by 13.0% during the second quarter. Opaleye Management Inc. now owns 2,895,467 shares of the company's stock worth $20,905,000 after buying an additional 333,517 shares in the last quarter. AWM Investment Company Inc. acquired a new stake in shares of Alpha Cognition in the 2nd quarter worth $12,073,000. Aristides Capital LLC boosted its position in shares of Alpha Cognition by 1.4% during the 1st quarter. Aristides Capital LLC now owns 218,510 shares of the company's stock valued at $1,200,000 after acquiring an additional 3,052 shares during the last quarter. Marshall Wace LLP purchased a new position in Alpha Cognition during the third quarter worth about $449,000. Finally, ACT Capital Partners L.P. purchased a new position in Alpha Cognition during the third quarter worth about $464,000.

Alpha Cognition Company Profile

(Get Free Report)

Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for people with neurodegenerative diseases and cognitive disorders. The company is based in Vancouver, British Columbia. Its lead product, ZUNVEYL (benzgalantamine), is an oral medication approved by the U.S. Food and Drug Administration to treat mild to moderate dementia of the Alzheimer's type. The company developed benzgalantamine as a prodrug of galantamine. Alpha Cognition is also developing ALPHA-1062 for potential use in other cognitive disorders, including cognitive impairment associated with traumatic brain injury.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alpha Cognition Right Now?

Before you consider Alpha Cognition, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.

While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines